Imaging as a strategy for premortem diagnosis and staging of tauopathies

Current Alzheimer Research

Volumn 7, Issue 3, 2010, Pages 230-234

  Kim, S ^a   Jensen, J R ^a   Cisek, K ^a   Funk, K E ^a   Naphade, S ^a   Schafer, K ^a   Kuret, J ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Frontotemporal lobar degeneration; Neurofibrillary tangle; Paired helical filaments; Tau

Indexed keywords

BENZOTHIAZOLE; BETA SECRETASE; THIOFLAVINE;

ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BINDING AFFINITY; BRAIN DAMAGE; FRONTOTEMPORAL DEMENTIA; HUMAN; NEUROFIBRILLARY TANGLE; NEUROIMAGING; PAIRED HELICAL FILAMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TAUOPATHY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BINDING, COMPETITIVE; BIOLOGICAL MARKERS; BRAIN; COLORING AGENTS; DIAGNOSTIC IMAGING; HUMANS; NEUROFIBRILLARY TANGLES; PROTEIN BINDING; TAU PROTEINS; TAUOPATHIES;

EID: 77952480429     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510791050894     Document Type: Article

References (53)

1. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, et al. Amyloid peptide load is correlated with increased -secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci USA 101: 3632-3637 (2004).
2. Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain A distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 158: 328-337 (1999).
3. Bramblett GT, Trojanowski JQ, Lee VM. Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent tau and accumulation of abnormal tau-isoforms (A68 proteins). Lab Invest 66: 212-222 (1992).
4. Greenberg SG, Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci USA 87: 5827-5831 (1990).
5. Khatoon S, Grundke-Iqbal I, Iqbal K. Brain levels of microtubule associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J Neurochem 59: 750-753 (1992).
6. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol (Berl) 82: 239-259 (1991).
7. Ghoshal N, Garcia-Sierra F, Wuu J, Leurgans S, Bennett DA, Berry RW, et al. Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease. Exp Neurol 177: 475-493 (2002).
8. Masliah E, Mallory M, Hansen L, DeTeresa R, Terry RD. Quantitative synaptic alterations in the human neocortex during normal aging. Neurology 43: 192-197 (1993).
9. Royall DR, Palmer R, Mulroy AR, Polk MJ, Roman GC, David JP, et al. Pathological determinants of the transition to clinical dementia in Alzheimer's disease. Exp Aging Res 28: 143-162 (2002).
10. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572-580 (1991).
11. Duyckaerts C, Hauw JJ. Prevalence, incidence and duration of Braak's stages in the general population: can we know? Neurobiol Aging 18: 362-369 (1997).
12. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol 45(1): 30-40 (2010).
13. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319 (2004).
14. Johnson AE, Jeppsson F, Sandell J, Wensbo D, Neelissen JA, Jureus A, et al. AZD2184: a radioligand for sensitive detection of-amyloid deposits. J Neurochem 108:1177-1186 (2009).
15. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical Properties of 18F-AV-45: A PET Agent for A Plaques in the Brain. J Nucl Med 50(11): 1887-1894 (2009).
16. Crowe A, Ballatore C, Hyde E, Trojanowski JQ, Lee VM. High throughput screening for small molecule inhibitors of heparininduced tau fibril formation. Biochem Biophys Res Comm 358: 1-6 (2007).
17. Defossez A, Delacourte A. Transformation of degenerating neurofibrils into amyloid substance in Alzheimer's disease: histochemical and immunohistochemical studies. J Neurol Sci 81: 1-10 (1987).
18. Schwab C, Steele JC, Akiyama H, McGeer EG, McGeer PL. Relationship of amyloid beta/A4 protein to the neurofibrillary tangles in Guamanian parkinsonism-dementia. Acta Neuropathol (Berl) 90: 287-298 (1995).
19. Uchihara T, Nakamura A, Yamazaki M, Mori O, Ikeda K, Tsuchiya K. Different conformation of neuronal tau deposits distinguished by double immunofluorescence with AT8 and thiazin red combined with Gallyas method. Acta Neuropathol (Berl) 102: 462-466 (2001).
20. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15: 217-227 (1984).
21. Fulton AB. How crowded is the cytoplasm? Cell 30: 345-347 (1982).
22. Tanemura K, Akagi T, Murayama M, Kikuchi N, Murayama O, Hashikawa T, et al. Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau. Neurobiol Dis 8: 1036-1045 (2001).
23. 11C]rolipram and positron emission tomography. Eur J Nucl Med Mol Imaging 29: 1680-1683 (2002).
24. Fowler JS, Logan J, Volkow ND, Wang GJ, MacGregor RR, Ding YS. Monoamine oxidase: radiotracer development and human studies. Methods 27: 263-277 (2002).
25. 18F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brain. Nucl Med Biol 36: 247-258 (2009).
26. Ginovart N, Meyer JH, Boovariwala A, Hussey D, Rabiner EA, Houle S, et al. Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain. J Cereb Blood Flow Metab 26: 330-344 (2006).
27. Itoh T, Abe K, Zoghbi SS, Inoue O, Hong J, Imaizumi M, et al. PET measurement of the in vivo affinity of 11C-(R)-rolipram and the density of its target, phosphodiesterase-4, in the brains of conscious and anesthetized rats. J Nucl Med 50: 749-756 (2009).
28. Zhou HX, Rivas G, Minton AP. Macromolecular crowding and confinement: biochemical, biophysical, and potential physiological consequences. Annu Rev Biophys 37: 375-397 (2008).
29. Ellis RJ. Macromolecular crowding: obvious but underappreciated. Trends Biochem Sci 26: 597-604 (2001).
30. Koshland DE. The key-lock theory and the induced fit theory. Angew Chem Int Ed Engl 33: 2375-2378 (1994).
31. Nelson R, Sawaya MR, Balbirnie M, Madsen AO, Riekel C, Grothe R, et al. Structure of the cross-beta spine of amyloid-like fibrils. Nature 435: 773-778 (2005).
32. Petkova AT, Yau WM, Tycko R. Experimental constraints on quaternary structure in Alzheimer's -Amyloid fibrils. Biochemistry 45: 498-512 (2006).
33. Wu C, Wang Z, Lei H, Duan Y, Bowers MT, Shea JE. The binding of thioflavin T and its neutral analog BTA-1 to protofibrils of the Alzheimer's disease A 16-22 peptide probed by molecular dynamics simulations. J Mol Biol 384: 718-729 (2008).
34. Wu C, Wang Z, Lei H, Zhang W, Duan Y. Dual binding modes of Congo red to amyloid protofibril surface observed in molecular dynamics simulations. J Am Chem Soc 129: 1225-1232 (2007).
35. Lockhart A, Ye L, Judd DB, Merritt AT, Lowe PN, Morgenstern JL, et al. Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on -amyloid peptide fibrils. J Biol Chem 280: 7677-7684 (2005).
36. Dähne S. Color and constitution: one hundred years of research. Science 199: 1163-1167 (1978).
37. Horobin RW, Bennion PJ. The interrelation of the size and substantivity of dyes; the role of van der Waals attractions and hydrophobic bonding in biological staining. Histochemie 33: 191-204 (1973).
38. Bird J, Brough N, Dixon S, Batchelor SN. Understanding adsorption phenomena: investigation of the dye-cellulose interaction. J Phys Chem B 110: 19557-19561 (2006).
39. King ME, Ahuja V, Binder LI, Kuret J. Ligand-dependent tau filament formation: implications for Alzheimer's disease progression. Biochemistry 38: 14851-14859 (1999).
40. Smith DL, Portier R, Woodman B, Hockly E, Mahal A, Klunk WE, et al. Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles. Neurobiol Dis 8: 1017-1026 (2001).
41. Kung MP, Skovronsky DM, Hou C, Zhuang ZP, Gur TL, Zhang B, et al. Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients. J Mol Neurosci 20: 15-24 (2003).
42. Ksiezak-Reding H, Wall JS. Characterization of paired helical filaments by scanning transmission electron microscopy. Microsc Res Technol 67: 126-140 (2005).
43. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33: 95-130 (2000).
44. Novak M, Kabat J, Wischik CM. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. EMBO J 12: 365-370 (1993).
45. Rademakers R, Cruts M, van Broeckhoven C. The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum Mutat 24: 277-295 (2004).
46. Ye L, Morgenstern JL, Lamb JR, Lockhart A. Characterisation of the binding of amyloid imaging tracers to rodent A fibrils and rodent-human A co-polymers. Biochem Biophys Res Comm 347: 669-677 (2006).
47. Johnson GV. Tau phosphorylation and proteolysis: insights and perspectives. J Alzheimers Dis 9: 243-250 (2006).
48. Yuzwa SA, Vocadlo DJ. O-GlcNAc modification and the tauopathies: insights from chemical biology. Curr Alzheimer Res 6: 451-454 (2009).
49. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10: 24-35 (2002).
50. Ashburn TT, Han H, McGuinness BF, Lansbury PT, Jr. Amyloid probes based on Congo Red distinguish between fibrils comprising different peptides. Chem Biol 3: 351-358 (1996).
51. Honson NS, Johnson RL, Huang W, Inglese J, Austin CP, Kuret J. Differentiating Alzheimer disease-associated aggregates with small molecules. Neurobiol Dis 363: 229-234 (2007).
52. Okamura N, Suemoto T, Furumoto S, Suzuki M, Shimadzu H, Akatsu H, et al. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci 25: 10857-10862 (2005).
53. Laruelle M, Slifstein M, Huang Y. Positron emission tomography: imaging and quantification of neurotransporter availability. Methods 27: 287-299 (2002).